# OnCo record bellwave-011 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/bellwave-011/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "bellwave-011", "NCT06136559" ;
  schema:name "BELLWAVE-011"@en ;
  schema:description "BELLWAVE-011 is Merck's bid to enter frontline CLL with a reversible BTK inhibitor, head to head against two approved covalent drugs."@en ;
  schema:url <https://onco.cc/trials/bellwave-011/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06136559> ;
  onco:status "recruiting" ;
  onco:phase "3" ;
  schema:startDate "2023-12-13" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/nemtabrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/> ;
  onco:companies <https://onco.cc/companies/merck/> .